Eli Lilly acquires another pain biotech, its 11th deal this year, as FDA eyes decision on once‑weekly PrEP pill

Eli Lilly announced the purchase of an Austin, Texas‑based pain biotechnology company, marking the 11th acquisition the Indianapolis‑based firm has completed in 2026. The deal expands Lilly's portfolio of pain‑management assets and reflects its ongoing strategy to broaden its pipeline through targeted biotech purchases.

The U.S. Food and Drug Administration has scheduled a decision date for a once‑weekly pre‑exposure prophylaxis (PrEP) pill, though the exact timing was not disclosed. The pending ruling is closely watched by investors and clinicians interested in new HIV prevention options.

The briefing also referenced other industry updates, including activities at Merck, MultiValent Biotherapies, Alvotech, enGene, Mirum, and Adaptive Biotechnologies, underscoring a busy period of development and partnership across the sector.